What medications can be used for osteoporosis in a 64‑year‑old woman with a FRAX hip fracture probability >4% who is intolerant of Evenity (romosozumab), Prolia (denosumab), and Forteo (teriparatide)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Oral Bisphosphonates Are Your First-Line Option

For this 64-year-old woman with high fracture risk (FRAX hip >4%) who cannot tolerate Evenity, Prolia, or Forteo, oral bisphosphonates (alendronate or risedronate) should be initiated immediately. 1, 2, 3

Treatment Algorithm

First-Line: Oral Bisphosphonates

  • Alendronate 70 mg weekly OR Risedronate 35 mg weekly 1, 2
  • These reduce hip fractures by 40-53% and vertebral fractures by 40-70% 1, 3
  • Strong recommendation with high-quality evidence for women with osteoporosis at high fracture risk 1
  • Generic formulations available, making them cost-effective 1, 3

Second-Line: IV Bisphosphonates

If oral bisphosphonates are not tolerated (GI symptoms, esophageal abnormalities, inability to remain upright 30 minutes):

  • Zoledronic acid 5 mg IV annually 1, 2
  • Equally effective for hip and vertebral fracture reduction 1
  • Watch for influenza-like symptoms after first infusion, hypocalcemia, and ensure adequate renal function 1

Third-Line: Selective Estrogen Receptor Modulators (SERMs)

If bisphosphonates are contraindicated or not tolerated:

  • Raloxifene 60 mg daily 2
  • Reduces vertebral fractures only (not hip or non-vertebral) 1
  • Critical caveat: Only appropriate if she has low risk of deep vein thrombosis and no history of stroke/MI 2
  • Consider if she has concurrent breast cancer risk, as raloxifene reduces breast cancer incidence 2
  • Strong recommendation AGAINST raloxifene from ACP due to thromboembolic risks 1

Fourth-Line: Hormone Therapy (Conditional)

Only if all above options fail and she meets ALL these criteria 2:

  • Under age 60 or <10 years past menopause (she's 64, so likely outside this window)
  • Low DVT risk
  • No prior MI/stroke
  • No breast cancer history
  • Has bothersome vasomotor symptoms
  • Has had hysterectomy (estrogen alone) or intact uterus (estrogen + progestin)

This is NOT recommended given ACP's strong recommendation against hormone therapy for osteoporosis treatment due to increased stroke, VTE, and breast cancer risks 1

Critical Implementation Points

Ensure Adequate Calcium and Vitamin D

  • Calcium: 1,200 mg daily (she's 64 years old) 4, 5
  • Vitamin D: 600-800 IU daily, target serum level ≥20 ng/mL 4, 5

Bisphosphonate-Specific Instructions

  • Take on empty stomach with full glass of water
  • Remain upright (sitting or standing) for 30 minutes after oral dose 4
  • Do not lie down to prevent esophageal irritation
  • Screen for contraindications: esophageal abnormalities, hypocalcemia, severe renal impairment (CrCl <35 mL/min for zoledronic acid) 1

Treatment Duration and Monitoring

  • Treat for 5 years initially 1
  • Reassess fracture risk at 3-5 years 2
  • If she remains high risk after 5 years, continue therapy
  • If risk decreases to low-moderate, consider bisphosphonate "holiday" 2
  • Do NOT monitor BMD during the first 5 years of treatment—fracture reduction occurs regardless of BMD changes 1

Why Not Other Options?

Abaloparatide

While effective, this is another anabolic agent similar to Forteo (teriparatide), which she's already intolerant of 2, 3. The mechanism and side effect profile are similar enough that cross-intolerance is likely.

Calcitonin

Only use as absolute last resort 2—weakest evidence, reduces only vertebral fractures, and should only be prescribed when all other treatments cannot be tolerated 2

Common Pitfalls to Avoid

  1. Don't skip bisphosphonates thinking she needs "stronger" therapy—her FRAX score of >4% hip fracture risk qualifies her for bisphosphonates, which have the strongest evidence base 1, 3

  2. Don't use raloxifene if she has ANY thromboembolic risk factors—the cardiovascular risks outweigh benefits in most patients 1

  3. Don't prescribe hormone therapy unless she's symptomatic and meets ALL safety criteria—the WHI trial showed increased serious cardiovascular events and breast cancer 1

  4. Don't monitor BMD frequently—it doesn't predict treatment response and leads to unnecessary treatment changes 1

  5. Don't forget to address adherence—bisphosphonates only work if taken correctly; discuss the importance of proper administration technique 1

References

4
Guideline

acog releases practice bulletin on osteoporosis.

American family physician, 2013

Related Questions

What are the recommended first‑line and subsequent medication options for adults with osteoporosis, including indications for oral bisphosphonates, denosumab, teriparatide, abaloparatide, and romosozumab?
For a patient with lumbar spine T‑score of –2.2, high FRAX fracture risk, long‑term bisphosphonate use, adequate vitamin D, and bone‑turnover markers showing elevated osteoclast activity with suppressed osteoblast activity, which is the best therapy: teriparatide alone, teriparatide plus denosumab, or teriparatide plus zoledronic acid (Reclast)?
Does moderate osteopenia require treatment?
What medication options are appropriate for a patient with osteoporosis who has sustained a provoked fracture?
What are the dosing, contraindications, and recommended treatment sequence for teriparatide, abaloparatide, and romosozumab in patients with osteoporosis at high or very high fracture risk?
In an 82-year-old patient with a normal echocardiogram who experienced a single 3.4-second sinus pause but is asymptomatic, what is the appropriate next step in management?
What instructions should I give the parents for administering hydroxyzine to a 5-year-old child weighing 50 lb (≈22.7 kg) before a laboratory visit?
What screenings should a 37-year-old woman with no high-risk conditions receive?
What is the appropriate management for a patient with new‑onset atrial fibrillation and a normal ventricular response?
In an 82‑year‑old patient on 120 mg verapamil who experienced a 3.4‑second sinus pause while resting, what is the appropriate management?
Is lamotrigine an effective first-line augmentation for unipolar depression with irritability and mood lability, and what is the appropriate dosing schedule?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.